All Updates

All Updates

icon
Filter
M&A
2seventy bio divests hemophilia A program to Novo Nordisk in asset purchase agreement
Human Gene Editing
Jun 27, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Human Gene Editing

Human Gene Editing

Jun 27, 2024

2seventy bio divests hemophilia A program to Novo Nordisk in asset purchase agreement

M&A

  • US biotech company 2seventy bio sold its hemophilia A program, along with rights to some of its gene-editing tech to Denmark-based pharmaceutical company Novo Nordisk. The transaction was valued at USD 40 million approximately.

  • This agreement grants Novo Nordisk access to 2seventy's hemophilia A treatment, as well as transfer of its in vivo gene-editing technology, including megaTAL technology, for non-oncology and non-autoimmune disease-related projects. Two of the staff members who were working on the hemophilia A program will also move to Novo Nordisk.

  • 2seventy plans to focus exclusively on the development and commercialization of its multiple myeloma treatment Abecma (idecabtagene vicleucel), a BCMA-targeted CAR T-cell therapy.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.